#ixazomib

Ixazomib (Mechanism of Action)

In this article, we will discuss Ixazomib (Mechanism of Action). So, let’s get started. Mechanism of ActionIxazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against…

In this article, we will discuss Ixazomib (Dosage Overview). So, let’s get started. IndicationsIxazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.DosageDosing and Administration GuidelinesIxazomib in combination with lenalidomide and dexamethasone The recommended starting dose…

Disponibile dall’11 marzo scorso, in Italia NINLARO® (ixazomib), il primo e unico inibitore orale del proteasoma per il trattamento del mieloma multiplo.

Ixazomib si presenta come capsula da assumere a domicilio una volta a settimana e apre una nuova prospettiva per i pazienti colpiti da mieloma multiplo, che potranno avere a disposizione una tripletta completamente orale. La combinazione di tre…

Takeda Gets Marketing Authorization for NINLARO™ (ixazomib) in Relapsed/Refractory Multiple Myeloma in Canada

August 8, 2016

Takeda Pharmaceutical Company Limited has announced Takeda Canada has received approval from Health Canada for NINLARO™ (ixazomib) capsules in combination with lenalidomide and dexamethasone for treating adult patients with multiple myeloma who have received at least one prior therapy. It is estimated that approximately 7,500 people live with multiple myeloma in Canada. The…